Lenvatinib

Generic Name
Lenvatinib
Brand Names
Lenvima 10, Kisplyx, Lenvima
Drug Type
Small Molecule
Chemical Formula
C21H19ClN4O4
CAS Number
417716-92-8
Unique Ingredient Identifier
EE083865G2
Background

Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular ...

Indication

Lenvatinib is indicated for the treatment of the following cancerous conditions:

Differentiated Thyroid Cancer (DTC)

Renal Cell Carcinoma (RCC)

Hepatocellular Carcinoma (HCC)

Endometrial Carcinoma

Associated Conditions
Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)
Associated Therapies
-
Clinical Trials
Related News

Phase II Study of Single Agent Lenvatinib

Phase 2
Conditions
Breast Cancer
Interventions
Drug: lenvatinib
First Posted Date
2017-05-30
Last Posted Date
2017-06-16
Lead Sponsor
National University Hospital, Singapore
Target Recruit Count
30
Registration Number
NCT03168074
Locations
🇸🇬

Nationa University Hospital, Singapore, Singapore

UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone

Phase 2
Suspended
Conditions
Thyroid Cancer
Interventions
Drug: Lenvatinib
Drug: Everolimus
First Posted Date
2017-05-04
Last Posted Date
2021-10-15
Lead Sponsor
Thomas Jefferson University
Target Recruit Count
5
Registration Number
NCT03139747
Locations
🇺🇸

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor

Phase 1
Completed
Conditions
Solid Tumor
Interventions
Drug: lenvatinib
First Posted Date
2017-01-04
Last Posted Date
2021-09-28
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
12
Registration Number
NCT03009292
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

🇨🇳

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery

First Posted Date
2017-01-02
Last Posted Date
2024-02-20
Lead Sponsor
Mayo Clinic
Target Recruit Count
3
Registration Number
NCT03008369
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma

First Posted Date
2016-12-30
Last Posted Date
2023-12-13
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
104
Registration Number
NCT03006926
Locations
🇺🇸

Mercy Medical Center, Baltimore, Maryland, United States

🇺🇸

Ronald Reagan UCLA Medical Center, Santa Monica, California, United States

🇺🇸

Icahn School of Medicine Mount Sinai, New York, New York, United States

and more 23 locations

Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors

Phase 1
Completed
Conditions
Solid Tumors
Interventions
Drug: lenvatinib
Drug: pembrolizumab
First Posted Date
2016-12-30
Last Posted Date
2021-05-20
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
6
Registration Number
NCT03006887
Locations
🇯🇵

Eisai Trial Site 1, Chuo-ku, Tokyo, Japan

Lenvatinib in Second Line Endometrial Carcinoma

Phase 2
Withdrawn
Conditions
Endometrial Neoplasms
Interventions
Drug: Doxorubicin
Drug: Lenvatinib
First Posted Date
2016-12-29
Last Posted Date
2016-12-29
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Registration Number
NCT03005015
Locations
🇨🇭

Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

First Posted Date
2016-11-28
Last Posted Date
2024-07-01
Lead Sponsor
Academic and Community Cancer Research United
Target Recruit Count
57
Registration Number
NCT02973997
Locations
🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

🇺🇸

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

and more 4 locations

A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China

First Posted Date
2016-11-17
Last Posted Date
2022-01-26
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
151
Registration Number
NCT02966093
Locations
🇨🇳

1025 Eisai Trial Site, Xiamen, Fujian, China

🇨🇳

1003 Eisai Trial Site, Guangzhou, Guangdong, China

🇨🇳

1006 Eisai Trial Site, Beijing, Beijing, China

and more 21 locations

Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)

First Posted Date
2016-11-03
Last Posted Date
2021-04-01
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
25
Registration Number
NCT02953743
Locations
🇨🇳

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

🇨🇳

Shanghai Cancer Hospital, Fudan University, Shanghai, Shanghai, China

🇨🇳

Zhongshan Hospital Fudan University, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy